Polyneuron Pharmaceuticals
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hochbergerstrasse 60c, Basel, Basel-City...Phone Number
+41 788371011Website
www.polyneuron.comRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Polyneuron Pharmaceuticals
Polyneuron Pharmaceuticals is a pioneering company focused on the precision treatment of antibody-mediated autoimmune diseases through its innovative Antibody-Catch technology platform. This platform enables the design of biodegradable injectable glycopolymers that selectively eliminate pathological autoantibodies while preserving the immune system. Founded in 2014 as a spin-off from the University of Basel, Polyneuron aims to address unmet medical needs in devastating autoimmune conditions, with its lead compound PN-1007 currently in Phase I clinical development. The company is dedicated to making a significant impact on the lives of patients suffering from these challenging diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Polyneuron Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Polyneuron Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Polyneuron Pharmaceuticals is spiking on competitors!
Check if Polyneuron Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Polyneuron Pharmaceuticals
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Polyneuron Pharmaceuticals has new funding data
Earning: See what the market has to say on Polyneuron Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Polyneuron Pharmaceuticals launches new products
Polyneuron Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Polyneuron Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Polyneuron Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Polyneuron Pharmaceuticals.
Polyneuron Pharmaceuticals financials insights
Gather financial insights about Polyneuron Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$3.1M
2020
Series A
$39.9M
Polyneuron Pharmaceuticals Tech Stack
A closer look at the technologies used by Polyneuron Pharmaceuticals
Most Recent Scoops
New Hire
Executive Move
Funding
Funding
Funding
Polyneuron Pharmaceuticals News & Media
Polyneuron and University of Basel Awarded Grant of CHF 1.2M to Advance Novel Treatments to ...
Polyneuron and University of Basel have received a CHF 1.2 million Innosuisse grant to support ABOi transplantation.Polyneuron Appoints Aled Williams as Chief Business Officer
BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron appoints Aled Williams as Chief Business OfficerPolyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M
Polyneuron Pharmaceuticals AG, a Basel, Switzerland-based clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, raised a CHF 14m extension of the Series A, bringing the total to CHF 36.5m. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by […] The post Polyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M appeared first on FinSMEs.Polyneuron Pharmaceuticals AG extends Series A financing
Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Polyneuron Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Polyneuron Pharmaceuticals is a pioneering company focused on the precision treatment of antibody-mediated autoimmune diseases through its innovative Antibody-Catch technology platform. This platform enables the design of biodegradable injectable glycopolymers that selectively eliminate pathological autoantibodies while preserving the immune system... Read More
